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Abstract: Background: Milk products fortified with vitamin D may constitute an alternative
to pharmacological supplements for reaching the optimal levels of serum 25-hydroxyvitamin D
[25(OH)D]. Our aim was to analyze the response of serum 25(OH)D and its predictive factors in
postmenopausal healthy women after a dietary intervention with a milk fortified with vitamin D
and calcium. Methods: We designed a prospective study including 305 healthy postmenopausal
women who consumed a fortified milk with calcium (900 mg/500 mL) and vitamin D3 (600 IU/500 mL)
daily for 24 months. Results: The 25(OH)D concentrations at 24 months were correlated to weight,
to body mass index, to the percentage of fat, triglycerides and to baseline 25(OH)D levels. We found
significant differences in the levels of 25(OH)D at 24 months according to baseline 25(OH)D levels
(p < 0.001) and body mass index (p = 0.019) expressed at quartiles. Multivariate analysis showed an
association between levels of 25(OH)D after the intervention and at baseline 25(OH)D (Beta = 0.47,
p < 0.001) and percentage of body fat (Beta = −0.227, p = 0.049), regardless of the body mass index.
Conclusions: In healthy postmenopausal women, the improvement in 25(OH)D after an intervention
with a fortified milk for 24 months depends mainly on the baseline levels of serum 25(OH)D and on
the percentage of body fat.
Keywords: Vitamin D; postmenopausal women; obesity; fat mass
1. Introduction
The Institute of Medicine (IOM) states that the Recommended Dietary Allowance (RDA) of
vitamin D is 15 µg (600 IU, international units) for 97.5% of the population aged 1–70, and 20 µg
(800 IU) for 97.5% of the population >70 years. These are the recommendations for achieving the
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circulating levels of 25-hydroxyvitamin D (25(OH)D) ≥ 20 ng/mL needed to maintain bone health [1].
However, other guidelines recommend serum levels of at least 20–30 ng/mL [2,3], and according to these
recommendations, many people are vitamin D deficient and will need vitamin D supplementation [4].
However, there is an important controversy about the target serum levels of 25(OH)D that must be
reached to achieve the maximum health benefits and how to supplement 25(OH)D in cases where it is
indicated [5].
The consumption of foods fortified with vitamin D is an alternative to treatment with
pharmacological supplements to reach the optimal serum levels of 25(OH)D. Factors influencing
the response to this strategy constitute an interesting area of research to optimize the nutritional
recommendations about fortified foods. Although there is no consensus, several clinical factors have
been reported to influence the dose–response relationships between vitamin D supplementation and
serum 25(OH)D [6,7], such as body weight, percentage of fat, age, baseline 25(OH)D levels, and type
and the duration of the intervention. In addition, genetic factors like single nucleotide polymorphisms
in the vitamin D-binding protein gene can also be significant [8].
Obesity is one of the main factors related to a lower response after vitamin D supplementation [7].
Different causes have been proposed to explain this finding, one of them is a decreased bioavailability
of vitamin D3 from skin and from dietary source due to its deposition in body fat compartments. Also,
an increased distribution volume for vitamin D has been proposed. Vitamin D deficiency is related to
obesity regardless of age and the latitude, and it is also independent of the cut-offs to define vitamin
D deficiency [9]. In the context of the increasing prevalence of obesity in the worldwide population,
a better knowledge of the relationship between obesity and vitamin D after nutritional interventions is
of interest.
Therefore, the aim of our study was to evaluate the changes occurring in serum 25(OH)D levels
and their predictive factors in postmenopausal Spanish women after a nutritional intervention with a
dairy product fortified with vitamin D.
2. Materials and Methods
2.1. Study Design
The findings presented in this study are a post-hoc analysis of data from a previously published
clinical trial [10]. Here we analyze the predictive factors of response of vitamin D after 24 months
of a nutritional intervention with a fortified milk with calcium (900 mg/500 mL) and vitamin D3
(600 IU/500 mL) on serum 25(OH)D. For this analysis, we selected 305 postmenopausal healthy women
(mean age 59 ± 6 years) who completed 24 months of follow up. Inclusion and exclusion criteria of the
study have been previously published [10].
Women consumed the dairy drinks for 24 months (500 mL/day, two intakes per day of 250 mL
each), in the context of their usual diet. Counselling about Mediterranean diet and physical activity
were provided to all women. The adherence to the intervention was evaluated every three months by
telephone calls and empty dairy containers were collected. Compliance with the intervention was above
90%. The dairy drinks were produced in white 1 L Tetra Bricks by Lactalis Puleva (Granada, Spain).
The study was approved by the Ethics Committee of Hospital Universitario San Cecilio of Granada.
All the volunteers provided informed written consent. The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki, following the EEC Good Clinical Practice guidelines
(July 1996).
2.2. Anthropometric Measurements
In the first visit anthropometric measurements were obtained, and also after 24 months of
intervention. We measured body weight (kg) using a standard balance beam scale (Seca), and body
height (cm) using a precision stadiometer (Seca), attached to the balance beam scale. Obesity was
defined as body mass index >30 kg/m2.
Nutrients 2019, 11, 2641 3 of 8
2.3. Body Composition Measurements
Skeletal muscle mass was estimated from bioelectrical impedance analysis (Tanita BC418) at
baseline and at 24 months after the onset of the intervention. This device calculates the percentage
of body fat, fat mass, fat-free mass, and the predicted muscle mass, based on the data obtained by
Dual-Energy X-ray Absorptiometry (DXA), using Bioelectrical Impedance Analysis with an operating
frequency of 50 kHz at 500 lA. Obesity was defined as percentage of fat mass above 35% [11].
2.4. Biochemical Parameters
Blood samples were obtained at 0 and at 24 months after a 12 hour overnight fast. The blood
was collected in a SST-Vacutainer (BD) and serum was separated by centrifugation at 3000 rpm for
15 min at 22–24 °C, then it was divided into aliquots and frozen and stored at −80 °C until analysis.
Serum total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides (TGs), glucose
levels, HbA1c, and apo B were determined by standard automated procedures (Biosystems, Barcelona,
Spain). LDL-c was calculated using the Friedewald formula. Serum 25(OH)D levels were measured by
chemiluminescence immunoassay from Diasorin (LIAISON® 25 OH Vitamin D TOTAL Assay).
2.5. Statistical Analyses
Data were evaluated for normality and homogeneity of variance, and they are expressed as
mean standard ± deviation. The relationship between serum vitamin D and biochemical and clinical
factors were assessed by univariate analysis. A logistic regression and multiple regression analysis
were performed to analyze the association between vitamin D levels at baseline and the levels found
after 24 months of intervention. The variables related to vitamin D after 24 months of intervention
(percentage of fat mass, weight, BMI, triglycerides and baseline 25 OH vitamin D) were included as
covariates. SPSS software (version 17.0, IBM, Armonk, NY, USA) was used for doing statistical analysis.
We considered p values < 0.05 as significant.
3. Results
Baseline clinical characteristics are shown in Table 1. Mean age was 59.3 ± 5.9 years.
Table 1. Characteristics of study subjects at baseline and after 24 months of intervention.
Baseline 24 months p
Weight (kg) 70 ± 11 70 ± 11 0.5
Body mass index (kg/m2) 28 ± 4 28 ± 4 0.084
Obesity (%) 28 32
Overweight (%) 47 48
Percentage of fat mass 37 ± 5 37 ± 5 0.047
Serum calcium (mg/dL) 9.7 ± 0.6 9.8 ± 0.6 <0.001
Parathyroid hormone (pg/mL) 57 ± 21 58 ± 20 0.102
25(OH)D (ng/mL) 22 ± 8 25± 6 <0.001
Total cholesterol (mg/dL) 214 ± 33 208 ± 32 <0.001
HDL colesterol (mg/dL) 55 ± 15 55 ± 14 0.62
LDL colesterol (mg/dL) 141 ± 32 135 ± 32 <0.001
Triglycerides (mg/dL) 87 ± 44 88 ± 46 0.6
3.1. Changes in Biochemical Parameters
Serum 25(OH)D concentrations increased significantly at 24 months compared to the baseline
values (25.4 ± 6.3 ng/dL vs. 21.7 ± 8.3 ng/dL, respectively, p < 0.001). At baseline, 51.3% of the women
had 25(OH)D concentrations > 20 ng/mL, and 14.1% > 30 ng/mL. After 24 months of intervention,
we observed a significant increase in the percentage of women with 25(OH)D levels > 20 ng/mL (78.5%)
and > 30 ng/mL (18.8%) compared to baseline, p < 0.001 for both.
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3.2. Factors Related to 25(OH)D Levels after the Intervention
Serum 25(OH)D levels at 24 months were correlated to weight (r = −0.243, p < 0.001), BMI
(r = −0.177, p = 0.006), percentage of fat mass (r = −0.32, p < 0.001), triglycerides (r = −0.301, p < 0.001)
and baseline 25(OH)D levels (r = 0.5, p < 0.001). (Figure 1). We found statistically significant differences
in the levels of 25(OH)D at 24 months according to baseline 25(OH)D (p < 0.001) and BMI (p = 0.019)
distributed by quartiles (Figure 2).
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Figure 2. The 25(OH) D levels at 24 months according to quartiles of baseline 25(OH) vitamin D (A)
and quartiles of body mass index (B).
We did not find differences in baseline 25(OH)D according to BMI: (<30 kg/m2) 21.9 ± 8 vs.
(>30 kg/m2) 21.3 ± 8.5, p > 0.05. However, lower 25(OH)D levels were observed in women with
BMI > 30 kg/m2 (24.1 ± 6.5 ng/mL) vs. those women with a BMI < 30 kg/m2 (26.2 ± 6 ng/mL) at
24 months (p = 0.026).
In women with obesity, defined by percentage of fat mass, baseline levels of 25(OH)D were lower
(21.2 ± 8.1 ng/mL) compared to women with percentage of fat mass below 35%: (24.6 ± 9 ng/mL),
p < 0.01. Women with obesity, defined by percentage of fat mass, also reached lower 25(OH)D levels
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after 24 months of intervention: 23.7 ± 5.9 ng/mL vs. 27.4 ± 5.9 ng/mL, p < 0.001, compared to women
with percentage of fat mass below 35%.
3.3. Multivariate Analysis
When we analyzed the probability of reaching adequate vitamin D levels after 24 months of
intervention, women with obesity (defined as BMI > 30 kg/m2 or percentage of fat mass above 35%)
have a higher risk of 25(OH)D < 20 ng/mL at 24 months: odds ratio (OR) 2.3, confidence interval,
CI, 95%: 1.2–4.4, p = 0.013 for BMI > 30 and OR 5, CI 95% 2–12.6, p < 0.001, for percentage of fat mass.
The influence of adiposity, defined as percentage of fat mass, in 25(OH)D levels after 24 months persisted
after adjusting for BMI: 25(OH)D < 20 ng/mL OR 4.5 CI 95% 1.6–12.3, p = 0.003, 25(OH)D < 30 ng/mL
OR 3.2 CI 95% 1.2–8.9, p = 0.02.
In women with percentage of fat mass above 35%, there was a 3.2 times higher probability of
reaching 25(OH)D levels < 30 ng/dL at 24 months, regardless of the BMI. However, when we adjusted by
baseline 25(OH)D levels, only the relationship with 25(OH)D < 20 ng/dL persisted (OR 3.6, CI 1.3–10.1,
p = 0.007).
In the multivariate analysis, we observed an association between serum 25(OH)D after 24 months
of intervention, baseline 25(OH)D levels (Beta = 0.47, p<0.001) and percentage of fat mass (Beta =−0.227,
p = 0.049), regardless of weight, BMI and triglycerides.
4. Discussion
The daily consumption of a dairy product providing 600 IU of vitamin D3 for 24 months is effective
to improve serum concentrations of 25(OH)D in healthy postmenopausal women. The nutritional
intervention described in our study allows that 78.5% of women reach 25(OH)D levels > 20 ng/mL,
and 18.8% of women reach 25(OH)D > 30 ng/mL. Baseline 25(OH)D levels and the percentage of
body fat mass are the main factors explaining the responsiveness. The risk of having 25(OH)D below
20 ng/mL after 24 months of intervention was 3.6 times higher in the women with fat mass above 35%,
regardless of BMI and baseline 25(OH)D levels.
This study shows that a simple nutritional intervention with a vitamin D3-enriched milk that
supplies 600 IU/day is effective in increasing 25(OH)D levels and helps to reach adequate 25(OH)D levels
in a high percentage of women. These results are comparable to those described when pharmacological
supplements of vitamin D were used, which often are not well tolerated by patients, especially if
combined with calcium [12]. Although there is not a total consistency regarding the adequate 25(OH)D
levels in healthy subjects [1–3,13], the most accepted serum values are 20 ng/mL, which will be reached
for most of the women after this intervention.
Basel concentrations of 25(OH)D influence the achievement of adequate 25(OH)D levels after
24 months, regardless of other factors. This fact reinforces previous data found in older [14,15] and
younger adults [16], and confirms the importance of considering baseline vitamin D in postmenopausal
healthy women who receive a nutritional intervention with vitamin D.
Another independent predictor of the response of 25(OH)D levels after 24 months of intervention
was body fat. Although weight, triglycerides and BMI showed and association with 25(OH)D levels at
24 months, only the percentage of fat mass persisted in multivariate analysis. BMI is a simple and
worldwide measurement of obesity. However, its validity has been discussed in recent years [17],
and other measures of fat may provide a better estimation of obesity, as percentage of fat mass. In the
present study, only the percentage of fat mass remained as an independent factor influencing the
response of vitamin D after the nutritional intervention, and not BMI. In older healthy women, fat mass
was negatively related to 25(OH)D in a cross-sectional study [18]. Our data showing an independent
association between the fat mass percentage and the evolution of 25(OH) D after 24 months confirms
this relationship, and reinforces the utility of this measurement when addressing the response to an
intervention with vitamin D. Other authors [16] found that body fat mass and BMI were not related the
25(OH)D response, speculating that total body mass instead than fat mass may determine the 25(OH)D
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response. The disparity in the results may be explained by the duration of the intervention and also by
the mean BMI of the subjects included in the study.
There is no agreement regarding why obesity would affect serum 25(OH)D levels. This influence
could be explained by a reduced intake of vitamin D, a reduced sun exposure, an increased storage
and/or sequestration of vitamin D in the adipose tissue. A volumetric dilution due to the distribution
of 25(OH)D in larger fat volumes [6,7,19,20]. In addition, vitamin D stored in the adipose tissue may be
less available for hydroxylation [14,16]. Therefore, if the increased prevalence of obesity worldwide is
the explanation for the high rates of hypovitaminosis D reported is a matter that should be investigated.
However, our study could not demonstrate a favorable effect of the consumption of a dairy product
supplemented with vitamin D on the loss of body weight or fat mass. This finding is consistent with
previously described findings [21].
Although BMI is the most widely used method to evaluate the presence of overweight and
obesity, it has been criticized because BMI does not always reflect true body fatness, that may be better
evaluated by the assessment of body fat and fat-free mass [22]. Bioelectrical impedance analysis is
considered as the simplest, most reproducible and least expensive method for the evaluation of body
composition in clinical practice. It has shown a high accuracy and an excellent correlation with DXA
when assessing the percentage of body fat [23]. Therefore, bioelectrical impedance is cost-effective and
feasible, and may replace DXA in assessing the body composition. Our results highlight the usefulness
of bioelectrical impedance analysis in the evaluation of healthy postmenopausal women. This analysis
may be useful in the selection of women at higher risk of vitamin D deficiency or in the selection of
women who need a higher supplementation of a more frequent evaluation of vitamin D levels.
Our results show that, in healthy postmenopausal women, baseline 25(OH)D levels and obesity,
defined as the percentage of fat mass, are independent determinants of 25(OH)D levels after 24 months
of a nutritional intervention, and they are of clinical relevance. These findings may allow a
better personalization of the supplementation with vitamin D for reaching adequate levels after
the intervention. Moreover, it has been described that the response to vitamin D may differ according
to the dose of vitamin D and the duration of the intervention [24]. Furthermore, the factors influencing
this response may differ between pharmacological and nutritional supplementation, and this potential
difference must be addressed. Considering our findings, the recommended vitamin D dose may be
adapted to baseline vitamin D levels. In addition, the estimation of the percentage of fat mass may be
better for predicting the response to nutritional interventions with vitamin D.
Our study has several strengths, as the long follow-up for a nutritional intervention, and the
exhaustive evaluation of compliance with the intervention. Limitations of the study are the absence
of a comprehensive assessment of dietary intake of vitamin D, which may influence the results.
However, women were advised not to change their lifestyle habits, and exercise was evaluated
semi-quantitatively and showed no changes during the intervention, as an example of no changes.
In addition, we evaluated Caucasian healthy women, and the generalization of this finding to males or
to other ethnic groups must be confirmed. Moreover, we only measured total 25(OH)D, and we did
not evaluate other metabolites.
5. Conclusions
In summary, the response of serum 25(OH)D levels to the supplementation with a fortified milk
consumed for 24 months depend on baseline levels of serum 25(OH)D and on the percentage of body
fat, regardless of BMI, in healthy postmenopausal women. In these women, the determination of the
percentage of fat mass by bioelectrical impedance may allow a better prediction of the response to
vitamin D after a nutritional intervention.
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